Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A)

Journal of Medicinal Chemistry

Volumn 55, Issue 7, 2012, Pages 3563-3567

  Blad, Clara C ^a   Van Veldhoven, Jacobus P D ^a   Klopman, Corné ^a   Wolfram, Dieter R ^a   Brussee, Johannes ^a   Lane, J Robert ^a,b   Ijzerman, Adriaan P ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 ISOPROPYLPHENYL) 7 METHYL N ( PHENOXYETHYL)PYRAZOLO[1,5 A]PYRIMIDIN 6 CARBOXAMIDE; 3 HYDROXYBUTYRIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109 A; NICOTINIC ACID; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PROTEIN FOLDING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SUZUKI REACTION;

3-HYDROXYBUTYRIC ACID; ALLOSTERIC REGULATION; DRUG SYNERGISM; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEK293 CELLS; HUMANS; NIACIN; PYRAZOLES; PYRIMIDINES; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859789565     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300164q     Document Type: Article

References (20)

1. Offermanns, S.; Colletti, S. L.; Lovenberg, T. W.; Semple, G.; Wise, A.; IJzerman, A. P. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B) Pharmacol. Rev. 2011, 63, 269-290
2. Schaub, A.; Futterer, A.; Pfeffer, K. PUMA-G, an IFN-gamma-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily Eur. J. Immunol. 2001, 31, 3714-3725
3. Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat. Med. 2003, 9, 352-355
4. Soga, T.; Kamohara, M.; Takasaki, J.; Matsumoto, S.; Saito, T.; Ohishi, T.; Hiyama, H.; Matsuo, A.; Matsushime, H.; Furuichi, K. Molecular identification of nicotinic acid receptor Biochem. Biophys. Res. Commun. 2003, 303, 364-369
5. Wise, A.; Foord, S. M.; Fraser, N. J.; Barnes, A. A.; Elshourbagy, N.; Eilert, M.; Ignar, D. M.; Murdock, P. R.; Steplewski, K.; Green, A.; Brown, A. J.; Dowell, S. J.; Szekeres, P. G.; Hassall, D. G.; Marshall, F. H.; Wilson, S.; Pike, N. B. Molecular identification of high and low affinity receptors for nicotinic acid J. Biol. Chem. 2003, 278, 9869-9874
6. Tunaru, S.; Lattig, J.; Kero, J.; Krause, G.; Offermanns, S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G) Mol. Pharmacol. 2005, 68, 1271-1280
7. Blad, C. C.; Ahmed, K.; IJzerman, A. P.; Offermanns, S. Biological and pharmacological roles of HCA receptors Adv. Pharmacol. 2011, 62, 219-250
8. Soudijn, W.; van Wijngaarden, I.; IJzerman, A. P. Nicotinic acid receptor subtypes and their ligands Med. Res. Rev. 2007, 27, 417-433
9. Shen, H. C.; Colletti, S. L. High-affinity niacin GPR109A receptor agonists Annu. Rep. Med. Chem. 2010, 45, 73-94
10. Shen, H. C.; Taggart, A. K. P.; Wilsie, L. C.; Waters, M. G.; Hammond, M. L.; Tata, J. R.; Colletti, S. L. Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A Bioorg. Med. Chem. Lett. 2008, 18, 4948-4951
11. +)-ATPase. 3. 3-Substituted-4-(phenylamino)quinolines J. Med. Chem. 1992, 35, 3413-3422
12. Springer, R. H.; Scholten, M. B.; O'Brien, D. E.; Novinson, T.; Miller, J. P.; Robins, R. K. Synthesis and enzymic activity of 6-carbethoxy- and 6-ethoxy-3,7-disubstituted pyrazolo[1,5-a]pyrimidines and related derivatives as adenosine cyclic 3′,5′-phosphate phosphodiesterase inhibitors J. Med. Chem. 1982, 25, 235-242
13. Bruni, F.; Selleri, S.; Costanzo, A.; Guerrini, G.; Casilli, M. L.; Giusti, L. Reactivity of 7-(2-dimethylaminovinyl)pyrazolo[1,5- a ]pyrimidines: synthesis of pyrazolo[1,5- a ]pyrido[3,4- e ]pyrimidine derivatives as potential benzodiazepine receptor ligands. 2 J. Heterocycl. Chem. 1995, 32, 291-298
14. Almansa, C.; de Arriba, A. F.; Cavalcanti, F. L.; Gómez, L. A.; Miralles, A.; Merlos, M.; García-Rafanell, J.; Forn, J. Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5- a ]pyrimidines J. Med. Chem. 2001, 44, 350-361
15. Cuny, G. D.; Yu, P. B.; Laha, J. K.; Xing, X.; Liu, J.-F.; Lai, C. S.; Deng, D. Y.; Sachidanandan, C.; Bloch, K. D.; Peterson, R. T. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4388-4392
16. Berger, D. M.; Torres, N.; Dutia, M.; Powell, D.; Ciszewski, G.; Gopalsamy, A.; Levin, J. I.; Kim, K.-H.; Xu, W.; Wilhelm, J.; Hu, Y.; Collins, K.; Feldberg, L.; Kim, S.; Frommer, E.; Wojciechowicz, D.; Mallon, R. Non-hinge-binding pyrazolo[1,5- a ]pyrimidines as potent B-Raf kinase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 6519-6523
17. Keov, P.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors: a pharmacological perspective Neuropharmacology 2011, 60, 24-35
18. Taggart, A. K.; Kero, J.; Gan, X.; Cai, T. Q.; Cheng, K.; Ippolito, M.; Ren, N.; Kaplan, R.; Wu, K.; Wu, T. J.; Jin, L.; Liaw, C.; Chen, R.; Richman, J.; Connolly, D.; Offermanns, S.; Wright, S. D.; Waters, M. G. (d)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G J. Biol. Chem. 2005, 280, 26649-26652
19. Richman, J. G.; Kanemitsu-Parks, M.; Gaidarov, I.; Cameron, J. S.; Griffin, P.; Zheng, H.; Guerra, N. C.; Cham, L.; Maciejewski-Lenoir, D.; Behan, D. P.; Boatman, D.; Chen, R.; Skinner, P.; Ornelas, P.; Waters, M. G.; Wright, S. D.; Semple, G.; Connolly, D. T. Nicotinic acid receptor agonists differentially activate downstream effectors J. Biol. Chem. 2007, 282, 18028-18036
20. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108